[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:recurrent-transformed-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":49,"states":50},"Recurrent Transformed Non-Hodgkin Lymphoma",6,4,[8,16,23,29,35,43],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05256641","Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:19:19.975067Z","2026-05-05T02:43:28.530741Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06765317","A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma",[20],"Phase 2","2026-08-26T02:16:59.895916Z","2026-05-05T02:43:28.346447Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[20],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[20],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":36,"title":37,"phases":38,"status":40,"updated_at":41,"content_modified":42},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[39],"Phase 1","ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z",{"nct_id":44,"title":45,"phases":46,"status":40,"updated_at":47,"content_modified":48},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[39],"2026-08-03T03:30:23.638222Z","2026-05-05T02:43:28.878051Z",[],[]]